# EDGAR Filing Document

**Accession Number:** 0001830487
**File Stem:** 0000000000-25-007777
**Filing Date:** 2025-7
**Character Count:** 4313
**Document Hash:** 92e01738362ccbe6877067ce99a71f47
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007777.hdr.sgml**: 20250924

**ACCESSION NUMBER**: 0000000000-25-007777

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250724

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharvaris N.V.
- **CENTRAL INDEX KEY:** 0001830487
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-40010

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7
- **BUSINESS PHONE:** 31 (0)71 203 6410

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** J.H. OORTWEG 21
- **STREET 2:** 2333 CH LEIDEN
- **CITY:** LEIDEN
- **PROVINCE COUNTRY:** P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pharvaris, B.V.
- **DATE OF NAME CHANGE:** 20201029
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950170-25-051347

## Text-Extract

```

                                                              July 24, 2025

Berndt Modig
Chief Executive Officer
Pharvaris N.V.
Emmy Noetherweg 2
2333 BK Leiden
The Netherlands

       Re: Pharvaris N.V.
           Form 20-F for Fiscal Year Ended December 31, 2024
           File No. 001-40010
Dear Berndt Modig:

       We have reviewed your filing and have the following comments.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 20-F for Fiscal Year Ended December 31, 2024
Item 4. Information on the Company
B. Business Overview, page 44

1.     We note your inclusion of a molecule named "PHAXXX" for an undisclosed
       indication in your pipeline table on page 47. In future filings, please
clarify if this
       refers to a specific molecule you are currently developing or if it is a
placeholder for
       future programs in early development. If it does refer to a specific
molecule, please
       revise future filings to provide more fulsome disclosure related to this
molecule,
       including the intended indication and any development steps you have
undertaken. To
       the extent it is a placeholder, tell us why it is sufficiently material
to your business to
       warrant inclusion in your pipeline table. Alternatively, remove any
programs that are
       not currently material to your business from your pipeline table in
future filings.
 July 24, 2025
Page 2
Item 5. Operating and Financial Review and Prospects
Research and development expenses, page 87

2.     We note that during 2024 both of your product candidates IR and XR began
Phase 3
       clinical trials. Please tell us and revise future filings to disclose
the costs incurred
       during each period presented for each of your key research and
development product
       candidates. If you do not track your research and development costs by
project,
       disclose that fact and explain why you do not maintain and evaluate
research and
       development costs by project in future filings.

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Please contact Eric Atallah at 202-551-3663 or Kevin Kuhar at
202-551-3662 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Tyler Howes at 202-551-3370 or Joshua Gorsky at 202-551-7836 with any
other
questions.

                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._